Argus Research Initiates Coverage on AstraZeneca plc (ADR)(NYSE:AZN). The shares have been rated Hold. The rating by Argus Research was issued on Jul 12, 2016.
In a different note, On May 2, 2016, Leerink Swann said it Maintains its rating on AstraZeneca plc (ADR). In the research note, the firm Lowers the price-target to $38.00 per share. The shares have been rated ‘Market Perform’ by the firm.
AstraZeneca plc (ADR) (AZN) shares turned negative on Fridays trading session with the shares closing down -0.1 points or -0.33% at a volume of 73,49,686. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $30.46. The peak price level was also seen at $30.46 while the days lowest was $30.12. Finally the shares closed at $30.24. The 52-week high of the shares is $34.88 while the 52-week low is $26.97. According to the latest information available, the market cap of the company is $76,507 M.
AstraZeneca plc (ADR)(AZN) last announced its earnings results on Apr 29, 2016 for Fiscal Year 2016 and Q1.Company reported revenue of $6.12B. Analysts had an estimated revenue of $5.96B. Earnings per share were $0.95. Analysts had estimated an EPS of $0.68.
AstraZeneca PLC (AstraZeneca) is a global biopharmaceutical company. The Company discovers develops and commercializes prescription medicines for cardiovascular and metabolic diseases; oncology; respiratory inflammation and autoimmunity and infection neuroscience and gastrointestinal. Its medicines include Crestor for managing cholesterol levels; Seloken/Toprol-XL for hypertension heart failure and angina; Iressa for lung cancer; Faslodex for breast cancer; Zoladex for prostate and breast cancer; Nexium for acid-related diseases; Seroquel XR for schizophrenia bipolar disorder and depressive disorder and Synagis for RSV (respiratory syncytial virus) a respiratory infection in infants. It also offers potassium-binding compound sodium zirconium cyclosilicate (ZS-9) a treatment for hyperkalaemia a condition associated with increased mortality in patients with chronic kidney disease (CKD) diabetes mellitus (DM) and chronic heart failure (CHF).